GlassScriptPhysician profile
Caroline M Behler
NPI 1518155357
$42,896.92
in general payments reported to CMS, 2019-2025
65 companies · $1,450 in 2025
The $1,450 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $3,300 · 2021: $4,984 · 2022: $1,584 · 2023: $2,824 · 2024: $2,341 · 2025: $1,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,226 · Consulting Fee: $2,085 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,225.82 |
| Consulting Fee | $2,084.75 |
| Education | $304.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $28,582.21 | 2019-2023 | Adcetris |
| Celgene Corporation | $2,105.21 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Abbvie INC. | $1,964.73 | 2019-2025 | Creon |
| Servier Pharmaceuticals LLC | $1,459.34 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $1,245.63 | 2019-2024 | Opdivo, Camzyos, Reblozyl |
| Pfizer INC. | $633.46 | 2019-2025 | |
| Exelixis INC. | $507.96 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $419.22 | 2019-2023 | Imbruvica, Epkinly |
| Janssen Biotech, INC. | $397.69 | 2019-2025 | Rybrevant, Tecvayli, Carvykti |
| Epizyme, INC. | $382.78 | 2021-2022 | |
| Incyte Corporation | $315.00 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $275.66 | 2019-2024 | Alunbrig, Fruzaqla |
| Gilead Sciences, INC. | $274.51 | 2021-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $271.42 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Alexion Pharmaceuticals, INC. | $269.84 | 2019-2025 | Ultomiris |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $268.36 | 2019-2024 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $265.92 | 2019-2024 | |
| Glaxosmithkline, LLC. | $244.90 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Amgen INC. | $224.39 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Astellas Pharma US INC | $218.16 | 2019-2024 | Xospata, Padcev |
| Lilly USA, LLC | $192.45 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genzyme Corporation | $154.26 | 2019-2024 | |
| Adc Therapeutics America, INC. | $144.25 | 2022-2025 | |
| Sirtex Medical INC | $119.91 | 2019 | |
| Taiho Oncology, INC. | $118.20 | 2021-2025 | |
| Eisai INC. | $117.29 | 2019-2025 | |
| Genentech USA, INC. | $112.00 | 2019-2025 | Polivy, Lunsumio, Phesgo |
| Rigel Pharmaceuticals, INC. | $110.49 | 2019-2025 | Tavalisse, Rezlidhia, Gavreto |
| Daiichi Sankyo INC. | $108.18 | 2020-2025 | Vanflyta, Enhertu |
| Sobi, INC | $102.86 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $80.52 | 2024-2025 | Onivyde |
| Bayer Healthcare Pharmaceuticals INC. | $76.11 | 2019-2025 | |
| Coherus Oncology, INC. | $72.93 | 2021-2024 | |
| Karyopharm Therapeutics INC. | $59.80 | 2020-2023 | Xpovio |
| Clovis Oncology, INC. | $58.34 | 2019-2021 | |
| Pharmacosmos Therapeutics INC. | $57.94 | 2021-2024 | Cosela |
| Pharmaessentia USA Corporation | $56.70 | 2023 | Besremi |
| Regeneron Healthcare Solutions, INC. | $49.54 | 2024-2025 | Libtayo |
| Puma Biotechnology, INC. | $45.62 | 2019 | |
| Agios Pharmaceuticals, INC. | $44.24 | 2019-2025 | Pyrukynd |
| Jazz Pharmaceuticals INC. | $43.57 | 2020-2021 | |
| Emd Serono, INC. | $42.87 | 2020-2021 | |
| Springworks Therapeutics, INC. | $40.79 | 2025 | Ogsiveo |
| Secura Bio, INC. | $38.41 | 2023-2024 | Copiktra |
| Octapharma USA, INC. | $38.28 | 2025 | Octagam Immune Globulin (Human) |
| Geron Corporation | $35.95 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $34.66 | 2025 | Orserdu |
| Acrotech Biopharma INC. | $32.38 | 2022 | |
| Blueprint Medicines Corporation | $30.29 | 2023 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $30.12 | 2025 | Romvimza, Qinlock |
| Legend Biotech USA INC. | $27.88 | 2025 | Carvykti |
| Syndax Pharmaceuticals, INC. | $27.38 | 2025 | Revuforj |
| Genmab U.S., INC. | $27.10 | 2025 | Epkinly |
| Beone Medicines USA, INC. | $26.83 | 2025 | Brukinsa |
| Kite Pharma, INC. | $23.44 | 2021 | |
| Mirati Therapeutics, INC. | $23.31 | 2024 | Krazati |
| Allergan, INC. | $22.50 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.12 | 2021 | |
| Apellis Pharmaceuticals, INC. | $22.09 | 2024 | Empaveli |
| Janssen Pharmaceuticals, INC | $19.18 | 2019 | |
| Tesaro, INC. | $16.63 | 2019 | |
| Verastem, INC. | $16.50 | 2019 | |
| Myriad Genetic Laboratories, INC. | $16.34 | 2023 | Precisetumor |
| Spectrum Pharmaceuticals INC. | $15.84 | 2019 | |
| Beigene USA, INC. | $14.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Behler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.